<code id='4EB75E8F32'></code><style id='4EB75E8F32'></style>
    • <acronym id='4EB75E8F32'></acronym>
      <center id='4EB75E8F32'><center id='4EB75E8F32'><tfoot id='4EB75E8F32'></tfoot></center><abbr id='4EB75E8F32'><dir id='4EB75E8F32'><tfoot id='4EB75E8F32'></tfoot><noframes id='4EB75E8F32'>

    • <optgroup id='4EB75E8F32'><strike id='4EB75E8F32'><sup id='4EB75E8F32'></sup></strike><code id='4EB75E8F32'></code></optgroup>
        1. <b id='4EB75E8F32'><label id='4EB75E8F32'><select id='4EB75E8F32'><dt id='4EB75E8F32'><span id='4EB75E8F32'></span></dt></select></label></b><u id='4EB75E8F32'></u>
          <i id='4EB75E8F32'><strike id='4EB75E8F32'><tt id='4EB75E8F32'><pre id='4EB75E8F32'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:entertainment    Page View:4495
          Illustration of two DNA strands made of banknotes. -- health coverage from STAT
          Adobe

          The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge a few times a year to scold drugmakers for pricing their latest cancer or MS advance far beyond reason.

          But last year, they sat down and concluded a forthcoming treatment was worth up to $3.9 million — more than any medicine in history, more than a 45-year supply of Humira, the autoimmune drug often held up as an emblem of America’s runaway drug spending. 

          advertisement

          It was a testament to the power of a new class of gene therapies to deliver something pharma so rarely does: Genuine cures. The treatment, approved last week as Lenmeldy, may allow some babies born with an ultra-rare neurodegenerative disease called metachromatic leukodystrophy, or MLD, to grow up and live essentially normal lives.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In